Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 874 results for "for merck"

Wall Street to open higher ahead of euro zone summit on Greece
Proactive Investors USA

Allergan To Acquire Worldwide Rights To Merck's Migraine Devel...

Allergan plc (AGN) and Merck (MRK) announced they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide receptor antagonists, ..., 4 hours ago
Allergan to Buy Merck Migraine Candidates for $250M+ Genetic Engineering News, 1 hour ago

828 images for for merck

Jutia Group, 17 minutes ago
WKRB News, 3 days ago
Proactive Investors USA, 1 hour ago, 1 day ago
EE Times Europe, 6 days ago
San Antonio, 2 days ago
The Times Of Israel, 1 week ago
Njbiz, 5 days ago
One News Page United Kingdom, 1 week ago
Springfield Patch, 6 days ago

Celgene's Move Into Merck's Former Campus Signals Next Stage Of Growth

 Seeking Alpha20 hours ago Celgene Buys Merck NJ Site Celgene Corp. has agreed to purchase the vacant 1.3 million-square-foot…  Pharmaceutical Manufacturing Magazine5 hours ago Celgene to take over former Merck headquarters in Summit  Fnews.com1 day ago Celgene Buys Merck's Summit Campus  PharmaAsia1 day ago
Sys-Con Media

Allergan (AGN) Slams Down $250 Million+ for Rights to Merck & Co. (MRK)'s Migraine Drugs 7/7/2015

-- Small-Molecule Program Includes Commercial Opportunities For the Treatment and Prevention of Migraine -- -- Strengthens Allergan's Pipeline of Innovative CNS Development Products -- -- Helps Position Allergan as Potential Migraine Treatment ...
 ClinicSpace3 hours ago Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program  News-Medical.Net3 hours ago Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program  Fat Pitch Financials4 hours ago Allergan Slams Down $250 Million+ for Rights to Merck & Co.'s Migraine Drugs  BioSpace2 hours ago

Merck announces encouraging results from Phase III CINV study

Merck has announced encouraging results from a Phase III study investigating the safety and efficacy of single-dose EMEND for injection, its substance P/neurokinin, or NK-1, receptor antagonist, in combination with other anti-vomiting medicines, for ...
 Individual.com22 hours ago Merck Highlights Phase 3 Study of Single-Dose EMEND [Professional Services Close - Up]  Pharmacy Choice4 hours ago Merck's phase 3 study of single-dose Emend for injection regimen meets primary endpoint in prevention of CINV in patients receiving MEC  PharmaBiz6 days ago
ACQ Magazine

One Put, One Call Option To Know About for Merck & Co.

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from ...
 Austin American Statesman23 hours ago
Sys-Con Media

Global Cancer Vaccines Market 2015-2019 - Strategic Alliances with Dendreon, GSK & Merck Dominating

( has announced the addition of the "Global Cancer Vaccines Market 2015-2019" report to their offering. The global cancer vaccines market to grow at a CAGR of 27.24% over the period ...
 Fat Pitch Financials3 hours ago Research and Markets Adds Report: Global Cancer Vaccines Market 2015-2019 With Dendreon, GSK & Merck Dominating  Individual.com4 days ago Veterinary Vaccines Market worth $7,197.9 Million by 2020  TradingCharts.com6 hours ago Animal Parasiticide Market: Global Industry Analysis and Opportunity Assessment 2015-2025  Digital Journal21 hours ago

Allergan nabs rights to Merck's CGRP receptor agonists for migraines for $250M

Allergan nabs rights to Merck's CGRP receptor agonists for migraines for $250M 7/7/2015, 12:52 PM (Source: Seeking Alpha) Allergan (NYSE: AGN ) acquires the worldwide rights to Merck's (NYSE: MRK ) investigational ...
 TeleTrader.com3 hours ago

Merck (MRK) Showing Bearish Technicals With Support At $57.00

Merck & Co Inc. ("MRK) presents a trading opportunity that offers a 3.10% return in just 74 days. A covered call on Merck at the $57.50 level expiring on Sep. '15 offers an assigned return rate of ...
 Individual.com1 day ago

Delhi HC resumes trial in Glenmark-Merck Sharp and Dohme patent case

A file photo of the Delhi high court. Photo: Arvind Yadav/HT New Delhi: The Delhi high court on Monday began hearing arguments in a patent dispute between Glenmark Pharmaceuticals Ltd and US-based Merck Sharp and Dohme, a unit of Merck and Co.
 Livemint.com1 day ago

Pfizer and Merck are Big Pharma's crown jewels

Matein Khalid / 6 July 2015 In Big Pharma, as elsewhere in the stock exchange, I prefer to buy fear and sell greed, not vice-versa! Lord Carrington once quipped The Queen's at ...
 Khaleej Times1 day ago Big pharma​ bosses front up to Senate inquiry into corporate tax avoidance  Canberra Times5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less